M2S, a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company has acquired DXA Resource Group (DRG) of Westborough, Mass.
M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company has acquired DXA Resource Group (DRG) of Westborough, Mass.
Founded in 2002, DRG recognized the need for cost-effective and responsive DXA (Dual- Emission X-Ray Absorptiometry) clinical quality assurance], project management and data management services to support drug development. DXA, a low-dose (1/10th of traditional x-ray) imaging modality that measures bone mineral density and body mass composition, is increasingly utilized in clinical trials to assess the safety and effectiveness of drugs under development for indications such as osteoporosis, HIV, obesity, growth hormone deficiency, endometriosis, fibroids and Gaucher’s disease.
“DRG has integrated quality service with imaging data technology, which exactly fits into the M2S mission and clinical trials image management service offering. The addition of DRG allows M2S to further expand our capabilities and therapeutic expertise, and meet the growing demand for image management services worldwide,” M2S CEO Wes Chapman said.
“Adding M2S high-speed image collection and trial management technologies to DRG’s proprietary quality system and data management, enables us to greatly increase our presence in the drug development market,” said Reta Rupich, President of DXA Resource Group.
About M2S, Inc.
M2S provides image and data management services for clinical trials sponsors in the biopharmaceutical and medical device industries, patient registry databases and is a recognized leader in 3-D endovascular treatment planning. For the past 10 years, M2S has managed, under protocol, millions of images from around the globe in various therapeutic areas and in all DICOM modalities. For more information, visit www.m2s.com.
About DXA Resource Group
DXA Resource group is a clinical trials service company focused on providing customer-centric, cost-effective quality assurance as well as data and project management for clinical trials involving Dual X-ray Absorptiometry (DXA) measurements. For more information visit www.dxaresourcegroup.com or www.m2s.com.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ifinatamab Deruxtecan Shows High Response Rates for Heavily Pretreated Small Cell Lung Cancer
September 9th 2024Potential first-in-class B7-H3 directed antibody drug conjugate ifinatamab deruxtecan shows potential to improve outcomes for patients living with difficult-to-treat form of lung cancer.